LDN Social Media
Get connected with us on social networks
Opiate Receptor Drugs – To Cycle or Not to Cycle Dosing? - Paul Anderson, NMD (2021 Conference) (LDN, low dose naltrexone)
Dr. Anderson talks about the use of Low Dose Naltrexone when treating cancer patients and those with chronic autoimmune disease, specifically using cyclic dosing. Dr. Anderson uses research and his own clinical experience to explain the nuances of how, when, and why he uses cyclic dosing of LDN.
KEYWORDS: LDN, Low Dose Naltrexone, Naltrexone, autoimmunity, oncology, opiate receptor drugs, cyclic dosing, cancer, pain syndromes, fibromyalgia, Chronic Fatigue Syndrome, Multiple Sclerosis, progressive MS, arthritis, autoimmune syndromes, neuropathy, GI health, endocrine balance, immune system
This is a summary of the presentation. Click on the video for full information.